How to develop differentiated therapies cost effectively: NCEs, repositioned drugs or both?

June 23, 2015Blog

Andreas Persidis, CEO Everybody agrees that the success of a drug increasingly depends on the total value it delivers. The commercial performance to date of Lundbeck’s antidepressant Brintellix is a case in point. Having demonstrated statistically significant efficacy over placebo in study results reported in 2012, Brintellix was approved by the FDA in 2013. Brintellix’s … Read More

New Biovista Inc. Publication: EMR Data Confirm Big Data Analytics Prediction That Hypothyroidism is a Risk Factor for New-onset Diabetes Mellitus

June 23, 2015Press Releases

CHARLOTTESVILLE, Virginia, June 23, 2015 /PRNewswire/ — French version    German version Biovista Inc. today announced the publication of data from research it carried out in collaboration with the FDA and Israeli HMO Clalit, focusing on the prediction of risk factors related to targeted diseases. The research, published in the American Diabetes Association journal Diabetes … Read More